Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Tax Provisions (2017 - 2025)

Corcept Therapeutics (CORT) has disclosed Tax Provisions for 9 consecutive years, with -$14.4 million as the latest value for Q4 2025.

  • Quarterly Tax Provisions fell 1285.26% to -$14.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$33.2 million through Dec 2025, down 263.99% year-over-year, with the annual reading at -$33.2 million for FY2025, 263.62% down from the prior year.
  • Tax Provisions hit -$14.4 million in Q4 2025 for Corcept Therapeutics, down from -$4.4 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $7.7 million in Q4 2022 to a low of -$14.4 million in Q4 2025.
  • Historically, Tax Provisions has averaged $1.6 million across 5 years, with a median of $4.7 million in 2021.
  • Biggest five-year swings in Tax Provisions: soared 412.16% in 2023 and later crashed 1285.26% in 2025.
  • Year by year, Tax Provisions stood at $4.7 million in 2021, then skyrocketed by 63.46% to $7.7 million in 2022, then decreased by 28.92% to $5.5 million in 2023, then tumbled by 77.74% to $1.2 million in 2024, then plummeted by 1285.26% to -$14.4 million in 2025.
  • Business Quant data shows Tax Provisions for CORT at -$14.4 million in Q4 2025, -$4.4 million in Q3 2025, and -$3.5 million in Q2 2025.